Oral presentation
Predictors of lung transplant complications
Chairs
A. Fisher
Newcastle-upon-Tyne
(United Kingdom)
08:30
LATE-BREAKING ABSTRACT: Prospective randomised pilot study to investigate the clinical effect of orally inhaled AP301 on treatment of primary graft dysfunction (PGD) in patients after primary lung transplantation (LuTX)
C. Aigner(Vienna, Austria)
COI
1
08:45
Alveolar macrophages and pulmonary microbiota are interconnected indicators of lung ecology post-transplantation
E. Bernasconi(Lausanne, Switzerland)
COI
2
09:00
The impact of long-term air pollution and traffic on outcome after lung transplantation in Europe
D. Ruttens(Leuven, Belgium)
COI
3
09:15
A multi-omics data integration approach to identify a predictive molecular signature of CLAD
J. Pellet(Lyon, France)
COI
4
09:30
Role of 18F-FDG PET in Restrictive Allograft Syndrome after lung transplantation
R. Vos(Leuven, Belgium)
COI
5
09:45
HNP and CCSP protein levels are differentially regulated in BAL from patients with obstructive and restrictive chronic allograft dysfunctions
N. Smirnova(München, Germany)
COI
6
10:00
Determining factors for bronchial healing in lung transplantation
A. Olland(Strasbourg, France)
COI
7
10:15
A mechanistic study on the effect of azithromycin on T helper-17 cells
E. Vandermeulen(Leuven, Belgium)
COI
8
. . .
